Derek Archila, an analyst from Wells Fargo, maintained the Buy rating on Kymera Therapeutics. The associated price target remains the same with $53.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Derek Archila’s rating is based on the promising developments in Kymera Therapeutics’ KT-621 program. The management’s positive commentary on the Phase 1b study, despite some uncertainties around dosing, suggests a high probability of success. The addition of a second dose and the introduction of a follow-on STAT6 degrader indicate ongoing innovation and adaptability in their approach, which could enhance the drug’s efficacy and market potential.
Furthermore, the company’s financial position is strong, with a significant cash reserve to support ongoing and future projects. The anticipation of “dupi-like” efficacy in the upcoming Phase 1b data release for atopic dermatitis, coupled with Kymera’s strategic advantage in owning full rights to the asset, positions the stock favorably. These factors contribute to Archila’s confidence in a potential upward movement in the stock price as the data release approaches.
In another report released yesterday, BTIG also maintained a Buy rating on the stock with a $59.00 price target.
KYMR’s price has also changed slightly for the past six months – from $34.410 to $37.680, which is a 9.50% increase.